Swindells S, et al. - In this randomized, open-label, phase 3 noninferiority trial, researchers assessed the outcomes of one-month rifapentine plus isoniazid vs isoniazid alone in prevention of tuberculosis in 3,000 HIV-infected patients. They observed comparable consequences of a 1-month regimen of rifapentine plus isoniazid vs 9 months of isoniazid alone in terms of preventing tuberculosis in HIV-infected patients. They also found a higher percentage of subjects in the 1-month group completed treatment. They also found severe adverse events in 6% of the subjects in the 1-month group vs 7% of those in the 9-month group.